

# Journal of Pharma Research Available online through www.jprinfo.com

Research Article ISSN: 2319-5622

## Formulation and Evaluation of Bilayered tablets of Loperamide Hcl and Simethicone

Pittla Yogitha\*, Raju. Manda, Dr. Suthakaran. R

Teegala Ram Reddy College of Pharmacy, Meerpet Hyderabad- 500097, Telangana (State). INDIA.

## Received on: 16-10-2014; Revised and Accepted on: 29-10-2014

## ABSTRACT

The purpose of the present study is to prepare and characterize once-daily immediate release tablets of Simethecone and Loperamide using different Super disintegrants. Bulk drugs were characterised for preformulation studies. Formulations were evaluated for the release of Simethecone and Loperamide over a period of 45 min using United States Pharmacopoeia (USP) type-II dissolution apparatus. The in-vitro drug release in 6.8P<sup>H</sup> Phosphate buffer as medium revealed that the most successful formulation of the study, S-L exhibited satisfactory in-vitro drug release. From the results it was evident that the Simethicone formulations prepared with super disintegrate Cross povidone showed maximum % drug release in 6 min i.e.98.97% (FS3 formulation and the concentration of super disintegrate is 15 mg) conatins Simethicone as drug. Formulation simethicone (FS3) was added to various formulations of Loperamide HCI .From the results it was evident that the Loperamide HCI formulations prepared with super disintegrate CCS showed maximum % drug release in 6 min i.e.99.84% (FT4 formulation and the concentration of super disintegrate is 20 mg) conatins Loperamide as drug along with simethicone(FS3). In conclusion, the results indicated that the prepared immediate release Bilayered tablets of Simethecone and Loperamide could perform therapeutically with improved efficacy.

Keywords: Simethicone, Loperamide, Crospovidone, CCS, Immediate release tablets.

#### INTRODUCTION

Loperamide is an anti-diarrhoeal agent. It has direct antisecretory effect on myentericopiate receptors in the gut <sup>[1]</sup>. Loperamide has minimal systemic availability (0.3%), with most of the drug being removed by first-pass metabolism [2], which further supports a local action in the gut. The main objective of the study is to investigate the best suitable dosage form of Loperamide in combination with simethicone and its method validation by HPLC. Historically, in preparing solid simethicone dosage forms, difficulties have been encountered when attempting to incorporate substantial quantities of liquid simethicone to solid final blend such as insufficient flow ability, hardness of tablet and not uniform distribution throughout. In the present the study an attempt will be made to design and evaluation of fast dissolving tablets of loperamide hydrochloride (an anti-diarrhoeal drug as an adjunct in the management of acute and chronic diarrhoeas and may also be used in the management of colostomies to reduce the volume of discharge) using synthetic disintegrants. It is having half life of 10 hours and its bioavailability is 40%, undergoes first-pass metabolism. So it is suitable candidate for design and evaluation of fast dissolving tablets by direct compression method, effervescent technique and sublimation method to improve its bioavailability and patient compliance and similar to simethicone.

## MATERIALS AND EQUIPMENTS

#### Materials:

Simethicone is obtained from ARCH Labs Loperimide is obtained from ARCH Labs Micro Crystalline Cellulose is obtained from NRchemicalsMumbai Sodium Starch Glycolate is obtained from Essel chem Mumbai

#### **Equipments:**

16 stations Compression Machine is supplied Rimek mini press-I, Mumbai Digital weighing balance is supplied by Shinko

### \*Corresponding author: Pittla Yogitha Department of Pharmaceutics, Teegala Ram Reddy College of Pharmacy, Meerpet -500097,

Telangana,(State) India. Mobile Number: 9032679048. \*E-Mail: yogi.angel4@gmail.com denshi co.LTD, japan. Hardness Tester is supplied by Cintex, Ind. Corporation, Mumbai Dissolution Apparatus, USP is supplied by DBK instruments, Mumbai. UV-Visible Spectrophotomter is supplied by Systronics UV-Vis Friability Tester is supplied by Veego (VFT 2D) model. Hot air oven is supplied by Cintex, Ind. Corporation, Mumbai.

#### Formulation and Evaluation methods:

Formulation of Tablets(Wet granulation method for Simethicone and Direct compression method for Loperamide HCl). Evaluation of Tablets Properties of Tablets –Appearance, Size and Thickness, Hardness, Friability, Weight variation, Content uniformity, *In-vitro* Drug Release Studies and Stability Studies.

MATERIALS	FS1(mg)	FS2(mg)	FS3(mg)	FS4(mg)
Simethicone	125	125	125	125
Lactose	40	40	40	40
Crosspovidone	5	10	15	20
PVP	24	24	24	24
Iso propanol	q.s	q.s	q.s	q.s
MCC	52.5	47.5	42.5	37.5
Magnesium	1.5	1.5	1.5	1.5
stearate				
Talc	1.5	1.5	1.5	1.5
Lake	0.5	0.5	0.5	0.5
colour(colourant)				
Tablet	250	250	250	250
weight(mg)				

# Formulation of Simethicone Dispersible Tablet by wet granulation method: Procedure:

Take 125mg of Simethicone to it add required quantity of Lactose and Crosspovidone, mix it well. Prepare the binder by taking 24mg of pvp in q.s isopropanol, mix well, add 0.5mg lakecolour (colourant) stir it well. Now add drop by drop binder to mixture until it forms wet mass note the volume of binder. Now make them granules by passing it through sieve no. 22. Dry the granules in oven at 60°c for 30min.Now sieve the dried granules by passing it through sieven.44 by adding talc, magnesium stearate. Mix it well and store it in suitable container. The blend is compressed using rotary tablet machine-8 station with 6mm flat punch, B tooling, Each

## Pittla Yogitha et al., J. Pharm. Res. 2014, 3(10), 204-208

tablet contains 2 mg Loperamide HCl and other pharmaceutical ingredients.

<b>Table No. 2: Composition</b>	of Loperamide HCl layer
---------------------------------	-------------------------

INGREDIENT	F1	F <sub>2</sub>	F <sub>3</sub>	F4	F <sub>5</sub>	F <sub>6</sub>	F <sub>7</sub>	F <sub>8</sub>	F9	F10	F11	F12
Loperamide HCl	2	2	2	2	2	2	2	2	2	2	2	2
CCS	5	10	15	20	-	-	-	-	-	-	-	-
SSG	-	-	-	-	5	10	15	20	-	-	-	-
Crosspovidone	-	-	-	-	-	-	-	-	5	10	15	20
Talc	2	2	2	2	2	2	2	2	2	2	2	2
Mg. Stearate	2	2	2	2	2	2	2	2	2	2	2	2
MCC	39	34	29	24	39	34	29	24	39	34	29	24
Mannitol	50	50	50	50	50	50	50	50	50	50	50	50
TOTAL(mg)	100	100	100	100	100	100	100	100	100	100	100	100

All ingredients are expressed in mg only.

Composition of preliminary trials for Loperamide HCl Dispersible Tablet by direct compression is shown in above table. All the ingredients were weighed. Required quantity of drug and excipient mixed thoroughly in a polybag. Store it in suitable container. In this method required quantity of drug and various concentrations of super disintegrants according to formulations were weighed, mixed thoroughly and milled after that diluent, lubricants and glidants were added and mixed well, sieved and stored it in a poly bag(suitable container)

#### **Compression:**

Pour required quantity (different formulations) of Simethicone granules in round flat faced punch in the die cavity of tablet press using spatula, Simethicone layer was pre-compressed to

## **RESULTS AND DISCUSSION**

Fourier Transform-Infrared Spectroscopy:

produce uniform layer. Now pour 100mg of Loperamide HCl powder (different formulations) in the same cavity having uniform Simethicone layer by using spatula, finally compressed with 6mm round flat punch. To obtain a tablet of optimum hardness and thickness.Bilayered tablets are formed collect them and store in suitable containers.

#### Spectroscopic studies:

UV Spectroscopy - Determination of  $\lambda$ max and Preparation of Calibration Curve of Simethicone by using Phosphate buffer pH 6.8, shows  $\lambda$ max at 278nm, $\lambda$ max of Loperamide HCl is determined by using Phosphate buffer pH 6.8shows  $\lambda$ max at 388 nm.




Fig. 1: FT-IR Spectrum of Loperamide HCl pure drug




Fig. 2: FT-IR Spectrum of Simethicone pure drug




Fig. 3: FT-IR Spectrum of Optimized Formulation

## Pittla Yogitha et al., J. Pharm. Res. 2014, 3(10), 204-208

From the FTIR data it was evident that the drug and super they were compatible. disintegrates, other excipients doses not have any interactions. Hence

#### Evaluation Parameters for Fast Dissolving Tablets of Loperamide HCl and Simethicone:

### Table No. 3: Pre-compression parameters for Simethicone

Pre-compression parameters Simethicone						
Formulations	Bulk Density (gm/cm²)	Tap Density (gm/cm²)	Carr's Index (%)	Hausner ratio	Angle Of Repose(θ)	
F1	0.62	0.71	12.67	1.14	26.2	
F <sub>2</sub>	0.64	0.73	12.32	1.13	27.5	
F <sub>3</sub>	0.66	0.71	7.04	1.07	19.8	
F4	0.64	0.74	13.5	1.19	20.8	

The data's were shown in above Table. The values for angle of repose were found in the range of  $19.8^{\circ}$ -27.5°. Bulk densities and tapped densities of various formulations were found to be in the range of 0.62 to 0.66 (gm/cc) and 0.71 to 0.74 (gm/cc) respectively. Carr's index of the prepared blends fall in the range of 7.04% to 13.5%. The Hausner ration fall in range of 1.07 to 1.19. From the result it was concluded that the powder blends had good flow properties and these can be used for tablet manufacture.

#### **Pre-compression parameters for Loperamide HCl:**

The data's were shown in below Table.The values for angle of repose were found in the range of  $22.34^{\circ}-29.72$ .°. Bulk densities and tapped densities of various formulations were found to be in the range of 0.40 to 0.51 (gm/cc) and 0.50 to 0.58 (gm/cc) respectively. Carr's index of the prepared blends fall in the range of 7.27% to 20%. The Hausner ration fall in range of 1.07 to 1.25. From the result it was concluded that the powder blends had good flow properties and these can be used for tablet manufacture

Table No. 4: Pre-compression parameters for Loperamide HCl

	Pre-compression parameters for Loperamide HCl						
Formulations	Bulk Density (gm/cm²)	Tap Density (gm/cm²)	Carr's Index (%)	Hausner ratio	Angle Of Repose(θ)		
F <sub>1</sub>	0.51	0.55	7.27	1.07	26.82		
F <sub>2</sub>	0.49	0.54	9.25	1.10	27.27		
F <sub>3</sub>	0.46	0.57	19.29	1.23	23.68		
F4	0.47	0.53	11.32	1.12	22.34		
<b>F</b> 5	0.49	0.58	15.51	1.18	29.72		
F <sub>6</sub>	0.48	0.58	17.24	1.20	26.14		
F7	0.47	0.58	18.96	1.23	28.84		
F8	0.43	0.51	15.68	1.18	25.24		
F9	0.40	0.50	20	1.25	22.31		
F <sub>10</sub>	0.43	0.51	15.68	1.18	26.92		
F <sub>11</sub>	0.48	0.56	14.28	1.16	25.38		
F <sub>12</sub>	0.41	0.50	18	1.21	25.94		

All the pre-compression parameters for Loperamide HCl were found to be within I.P limits.From the result it was concluded that the powder blends had good flow properties and these can be used for tablet manufacture.

#### **Post compression Parameters:**

The following are the post compression parameters as per IP limits Weight variation test, Hardness test, Thickness, Friability, In vitro disintegration time.

#### Invitro Dissolution studies:

Invitro dissolution studies were carried out by using 900ml of 6.8P<sup>H</sup> Phosphate buffer in USP dissolution apparatus by using paddle method. The dissolution studies were carried out for about 30 min.The dissolution data for simethicone given in below table and for all the formulations final tablet were given in the below Table after simethicone.




Fig. 4: Invitro dissolution data of simethicone

Table No. 5: Dissolution profile of simethicone formulations (FS)

Time (Min)	FS1	FS2	FS3	FS4
2	25.4	30.8	45.72	37.31
4	39.6	36.72	66.16	47.62
6	48.6	56.16	98.97	73.42
8	64.3	87.4		84.71
10	76.4	98.5		97.32
15	97.6			
20	97.1			

#### Dissolution profile of simethicone formulations (FS):

From the tabular column it was evident that the formulation prepared with super disintegrate cross povidone showed maximum % drug release in 6 min i.e.98.97% (Fs3 formulation and the concentration of super disintegrate is 15 mg).




Fig. 5: Invitro dissolution data of Final Tablet




Fig. 6: Dissolution profile of formulations prepared with CCS as super disintegrate




Fig. 7: Dissolution profile of formulations prepared with SSG as super disintegrate

# Dissolution profile of formulations prepared with Crospovidone:

From the tabular column mentioned above it was evident that the formulations prepared with super disintegrate CCS showed maximum % drug release in 6 min i.e.99.84% (FT4 formulation and the concentration of super disintegrate is 20 mg).The formulations prepared with SSG showed maximum percentage drug release in 8 min i.e., 98.4 % (FT8 formulation and the concentration of super disintegrate is 20 mg).The formulation's prepared with Crospovidone showed maximum percentage drug release in 8 min i.e.,99.4%,(FT12 formulation and the concentration of super disintegrate is 20 mg).Irrespective of super disintegrate type the disintegration time decreases and Dissolution time also decreases as the concentration of super disintegrate increases. The dissolution profile was represented in above graphs.

#### Stability studies:

From the results it was found that formulation FT4 is the best formulation amongst the 12 formulations. Thus formulation FT4 was selected for stability studies. The Hardness, Disintegration time and Percentage drug content of tablet after 1, 2, 3 months of stability studies were studied. The results are within the limits. The data is shown in below Table.

#### Table No. 6: Data for different evaluation tests of FT4 at the end of 1, 2, 3 month of stability


TIME PERIOD	Hardness (kg/cm2)	Friability (%)	Disintegration time (sec)	Drug content (%)
1st month	3.2±0.25	0.47±0.05	19±0.5	99.34±0.3
2 <sup>nd</sup> month	3.1±0.2	0.46±0.08	19±0.6	99.18±0.5
3 <sup>rd</sup> month	3.06±0.1	0.46±0.02	17±0.1	99.02±0.22

All the values are expressed as a mean  $\pm$  SD., n = 3

#### *IN-VITRO* dissolution study in 6.8 P<sup>H</sup> phosphate buffer:

Table No. 7: *In-vitro* dissolution profile of FT4 at the end of 1, 2, 3 month of stability

Sl. No.	Time (min)	% cumulative Drug Release			
		1 <sup>st</sup> month	2 <sup>nd</sup> month	3 <sup>rd</sup> month	
0	0	0	0	0	
1	2	96.3	95.24	95.9	
2	4	98.4	98.1	98.27	
3	6	99.72	99.21	98.96	



# Fig. 8: Stability studies invitro dissolution of FT4 for month 1,2,3

Stability studies of FT4 were performed (1,2,3 months) and there is no significant changes in it, values are under I.P limits only, hence it can be concluded that FT4 is stable. All the post compression parameters were found to be in I.P limits (for 3 months).No statistically significant differences were observed in Hardness, percentage drug content and cumulative percentage drug release in optimized formulation at the end of three months of stability studies. So it can be concluded that the formulation is stable for short term storage conditions

#### CONCLUSION

The objective of this work was to formulate bilayered tablets constituting Loperamide and Simethicone layers in immediate release forms. The tablets produced met with the I.P requirement regarding drug content uniformity, hardness, disintegration and friability. All the formulations produced were studied for their drug in dissolution media of 6.8 pH phosphate buffer. In conclusion, the results indicated that the prepared immediate release Bilayered tablets of Simethecone and Loperamide could perform therapeutically with improved efficacy. Stability studies of FT4 done for 3months and results were found to be in limit there are no significant changes, hence we can say FT4 as stable. Hence it can be concluded that preparations containing super disintegrate CCS (20mg) used was found to be the best formulation.

#### **REFERENCES:**

- Lachman Leon, Liberman H.A.and Kanig J.L., "The Theory and Practice of Industrial pharmacy", 3rd edn, Varghese publishing House Bombay, p. 453.
- Liberman, H. A. "Pharmaceutical Dosage Form; Tablets", 2nd edn, Vol. I, 201
- Aulton M.E. "Hand Book of pharmaceutics", 1st edn, 2001; Churchill Livingstone, 291-295.
- Chien Y. W., "Novel Drug Delivery System", 2nd edn, Revised and expanded, 1992; Marcel and Dekker Inc. New York, 139-140.
- Chien Y. W., "Novel Drug Delivery System", 2nd edn, Revised and expanded, 1992; Marcel and Dekker Inc. New York, 1-243.
- Remington Pharmaceutical Sciences, 28th edn, pg.860-870, 882-884.
- James Swarbrick, Encyclopedia of Pharmaceutical Technololgy, Informa healthcare, Vol 2, 3rd edn, 2007; 1242, 1248, 3707-370.
- Brahmankar, Sunil Jaiswal, Biopharmceutics and Pharmacokinetics a treatise Pharmaceutics, The science of dosage form design, Aulton M.E, 2<sup>nd</sup> edn: 398, 404-409.
- 9. Paul E.Sax,Calvin J.Cohen,Daniel R.Kuritzkes,Physician Press -HIV essentials, 3<sup>rd</sup> edn, **2010**; pp 17-24,197.
- Modern Pharmaceutics, Gilbert S.Banker Christopher T. Rhodes, 2nd edn, 1990.

## How to cite this article:

Pittla Yogitha et al.,: Formulation and Evaluation of Bilayered tablets of Loperamide Hcl and Simethicone. J. Pharm. Res., 2014; 3(10): 204-208.

Conflict of interest: The authors have declared that no conflict of interest exists. Source of support: Nil